Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.
Researchers showed that detectable ctDNA following chemoradiation may identify lung cancer patients who will likely have disease recurrence and should receive consolidation immunotherapy.
Researchers performed single-cell RNA sequencing and demonstrated that the emerging heterogeneity in SCLC necessitates optimal combination treatment strategies at the outset.
